{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:15Z","timestamp":1787019555819,"version":"build-2736575974"},"reference-count":43,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Denosumab (DNM) is a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) that has been licensed for the treatment of different types of osteoporosis. However, the prospective data for the evaluation of DNM efficacy on transfusion-dependent thalassemia (TDT)\u2013induced osteoporosis are rather limited. Thus, we conducted a randomized, placebo-controlled, double-blind, phase 2b clinical trial to evaluate DNM in TDT osteoporosis. Patients were assigned to receive either 60 mg DNM (n = 32) or placebo (n = 31) subcutaneously on day 0 and 180 during a total of 12 months of follow-up. The percentage increase of L1-L4 bone mineral density was higher in the DNM group than the placebo group (5.92% \u00b1 5.25% vs 2.92% \u00b1 5.56%, respectively; P = .043), whereas the advantage of DNM regarding wrist bone mineral density was much higher compared with placebo (\u22120.26% \u00b1 5.31% vs \u22123.92% \u00b1 8.71%, respectively; P = .035). No grade 3 or 4 toxicity was observed. DNM reduced pain scores that remained unaltered in the placebo group. DNM showed a significant reduction of soluble RANKL (sRANKL), sRANKL\/osteoprotegerin ratio, C-telopeptide of collagen type I, tartrate-resistant acid phosphatase isoform-5b, and bone-specific alkaline phosphatase between baseline and the 12th month (P &amp;lt; .01 for all comparisons) without changes in dickkopf-1, sclerostin, and osteocalcin. On the contrary, placebo patients showed an increase in sRANKL, osteoprotegerin, dickkopf-1, sclerostin, C-telopeptide of collagen type I, tartrate-resistant acid phosphatase isoform-5b, and bone-specific alkaline phosphatase during the study period (P &amp;lt; .01 for all comparisons). In conclusion, DNM increased lumbar spine and wrist bone mineral density and reduced pain and bone remodeling markers, and thus it is another valuable option for the management of TDT-induced osteoporosis. This trial was registered at www.clinicaltrials.gov as #NCT02559648.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018023085","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T11:51:19Z","timestamp":1540986679000},"page":"2837-2847","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial"],"prefix":"10.1182","volume":"2","author":[{"given":"Ersi","family":"Voskaridou","sequence":"first","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Center, \u201cLaiko\u201d General Hospital, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Papaefstathiou","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Second Department of Internal Medicine-Propaedeutic, Research Institute and Diabetes Center, National and Kapodistrian University of Athens School of Medicine, Athens, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Christoulas","sequence":"additional","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dimopoulou","sequence":"additional","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Center, \u201cLaiko\u201d General Hospital, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Repa","sequence":"additional","affiliation":[{"name":"Thalassemia and Sickle Cell Disease Center, \u201cLaiko\u201d General Hospital, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Papatheodorou","sequence":"additional","affiliation":[{"name":"Department of Biomedical Research, 251 General Air-Force Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melpomeni","family":"Peppa","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Second Department of Internal Medicine-Propaedeutic, Research Institute and Diabetes Center, National and Kapodistrian University of Athens School of Medicine, Athens, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,10,31]]},"reference":[{"key":"2020021108390466500_B1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.metabol.2017.09.012","article-title":"Bone disease in \u03b2 thalassemia patients: past, present and future perspectives","volume":"80","author":"De Sanctis","year":"2018","journal-title":"Metabolism"},{"key":"2020021108390466500_B2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/asheducation-2017.1.272","article-title":"Impact of bone disease and pain in thalassemia","volume":"2017","author":"Piga","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2020021108390466500_B3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-2141.1998.01108.x","article-title":"High prevalence of low bone mass in thalassaemia major","volume":"103","author":"Jensen","year":"1998","journal-title":"Br J Haematol"},{"issue":"1","key":"2020021108390466500_B4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6823-3-4","article-title":"Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran","volume":"3","author":"Shamshirsaz","year":"2003","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"2020021108390466500_B5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/nyas.13041","article-title":"Management of beta-thalassemia-associated osteoporosis","volume":"1368","author":"Giusti","year":"2016","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"2020021108390466500_B6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s001980170079","article-title":"Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major","volume":"12","author":"Lasco","year":"2001","journal-title":"Osteoporos Int"},{"issue":"1","key":"2020021108390466500_B7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00223-002-1044-3","article-title":"Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major","volume":"74","author":"Carmina","year":"2004","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"2020021108390466500_B8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00277-010-1007-0","article-title":"Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major","volume":"89","author":"Baldini","year":"2010","journal-title":"Ann Hematol"},{"issue":"4","key":"2020021108390466500_B9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1046\/j.1365-2141.2003.04657.x","article-title":"Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia","volume":"123","author":"Voskaridou","year":"2003","journal-title":"Br J Haematol"},{"issue":"9","key":"2020021108390466500_B10","first-page":"1193","article-title":"Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial","volume":"91","author":"Voskaridou","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"2020021108390466500_B11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00774-003-0435-5","article-title":"Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis","volume":"21","author":"Pennisi","year":"2003","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"2020021108390466500_B12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1046\/j.1365-2141.2001.02549.x","article-title":"Bone resorption is increased in young adults with thalassaemia major","volume":"112","author":"Voskaridou","year":"2001","journal-title":"Br J Haematol"},{"issue":"5","key":"2020021108390466500_B13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1359\/jbmr.040113","article-title":"Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle","volume":"19","author":"Morabito","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2020021108390466500_B14","first-page":"813","article-title":"Osteoporosis and osteosclerosis in sickle cell\/beta-thalassemia: the role of the RANKL\/osteoprotegerin axis","volume":"91","author":"Voskaridou","year":"2006","journal-title":"Haematologica"},{"issue":"8","key":"2020021108390466500_B15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"2020021108390466500_B16","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"issue":"2","key":"2020021108390466500_B17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00198-014-2964-2","article-title":"Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)","volume":"26","author":"Sugimoto","year":"2015","journal-title":"Osteoporos Int"},{"issue":"9","key":"2020021108390466500_B18","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9768","key":"2020021108390466500_B19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"35","key":"2020021108390466500_B20","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020021108390466500_B21","author":"Raje"},{"issue":"4","key":"2020021108390466500_B22","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4103\/2230-8210.137516","article-title":"Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis","volume":"18","author":"Yassin","year":"2014","journal-title":"Indian J Endocrinol Metab"},{"issue":"7889","key":"2020021108390466500_B23","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(74)90884-8","article-title":"Measurement of pain","volume":"2","author":"Huskisson","year":"1974","journal-title":"Lancet"},{"issue":"3","key":"2020021108390466500_B24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(75)90044-5","article-title":"The McGill Pain Questionnaire: major properties and scoring methods","volume":"1","author":"Melzack","year":"1975","journal-title":"Pain"},{"issue":"12","key":"2020021108390466500_B25","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1359\/jbmr.2001.16.12.2163","article-title":"Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture","volume":"16","author":"Chesnut","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2020021108390466500_B26","first-page":"94","article-title":"Interactions between osteoclasts, osteoblasts and immune cells: implications for the pathogenesis of bone loss in thalassemia","volume":"6","author":"Terpos","year":"2008","journal-title":"Pediatr Endocrinol Rev"},{"issue":"4","key":"2020021108390466500_B27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0609.2004.00395.x","article-title":"Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3","volume":"74","author":"Voskaridou","year":"2005","journal-title":"Eur J Haematol"},{"issue":"3","key":"2020021108390466500_B28","first-page":"902","article-title":"Bone mineral metabolism in adults with beta-thalassaemia major and intermedia","volume":"111","author":"Dresner Pollack","year":"2000","journal-title":"Br J Haematol"},{"issue":"4","key":"2020021108390466500_B29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/BF03344015","article-title":"Osteoporosis and beta-thalassemia major: role of the IGF-I\/IGFBP-III axis","volume":"25","author":"Lasco","year":"2002","journal-title":"J Endocrinol Invest"},{"issue":"21","key":"2020021108390466500_B30","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality--the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"2020021108390466500_B31","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3324\/haematol.2008.000893","article-title":"Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration","volume":"94","author":"Voskaridou","year":"2009","journal-title":"Haematologica"},{"issue":"12","key":"2020021108390466500_B32","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1055\/s-0032-1312618","article-title":"High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density","volume":"44","author":"Voskaridou","year":"2012","journal-title":"Horm Metab Res"},{"issue":"4","key":"2020021108390466500_B33","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00198-011-1675-1","article-title":"Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women","volume":"23","author":"Chung","year":"2012","journal-title":"Osteoporos Int"},{"issue":"1","key":"2020021108390466500_B34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1749-6632.2010.05542.x","article-title":"Treatment options for thalassemia patients with osteoporosis","volume":"1202","author":"Terpos","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"2020021108390466500_B35","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1359\/jbmr.2003.18.9.1682","article-title":"Abnormalities in bone mineral density and bone histology in thalassemia","volume":"18","author":"Domrongkitchaiporn","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020021108390466500_B36","first-page":"CD010429","article-title":"Treatment for osteoporosis in people with \u00df-thalassaemia","volume":"3","author":"Bhardwaj","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2020021108390466500_B37","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1007\/s00198-016-3719-z","article-title":"Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease","volume":"27","author":"Dede","year":"2016","journal-title":"Osteoporos Int"},{"issue":"7","key":"2020021108390466500_B38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","article-title":"Adverse effects of bisphosphonates: implications for osteoporosis management","volume":"84","author":"Kennel","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2020021108390466500_B39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bcp.12355","article-title":"The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review","volume":"78","author":"Sohn","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"2020021108390466500_B40","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s00198-015-3174-2","article-title":"Denosumab versus zoledronic acid in patients previously treated with zoledronic acid","volume":"26","author":"Anastasilakis","year":"2015","journal-title":"Osteoporos Int"},{"issue":"8","key":"2020021108390466500_B41","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2020021108390466500_B42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","article-title":"Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics","volume":"53","author":"Lipton","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"2020021108390466500_B43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1185\/030079903125003062","article-title":"Is bone mineral density predictive of fracture risk reduction?","volume":"20","author":"Cefalu","year":"2004","journal-title":"Curr Med Res Opin"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/21\/2837\/1629716\/advances023085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/21\/2837\/1629716\/advances023085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:12:52Z","timestamp":1581412372000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/21\/2837\/16165\/Denosumab-in-transfusiondependent-thalassemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,31]]},"references-count":43,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018,11,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018023085","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,31]]}}}